Search

Your search keyword '"Sridhar Natesan"' showing total 67 results

Search Constraints

Start Over You searched for: Author "Sridhar Natesan" Remove constraint Author: "Sridhar Natesan"
67 results on '"Sridhar Natesan"'

Search Results

1. Mitochondrial complex I density is associated with IQ and cognition in cognitively healthy adults: an in vivo [18F]BCPP-EF PET study

2. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study

3. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats

4. Evaluation of Intraperitoneal [18F]-FDOPA Administration for Micro-PET Imaging in Mice and Assessment of the Effect of Subchronic Ketamine Dosing on Dopamine Synthesis Capacity

5. Muscarinic receptor agonists in animal models of psychosis: protocol for a systematic review and meta-analysis [version 1; peer review: awaiting peer review]

6. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study

7. Time to re-evaluate the risks and benefits of valproate and a call for action

8. Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study

9. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse

10. The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients

11. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

12. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis

13. Contrasting effects of chronic lithium, haloperidol and olanzapine exposure on synaptic clusters in the rat prefrontal cortex

14. Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue

16. Mesocorticolimbic circuit mechanisms underlying the effects of ketamine on dopamine: a translational imaging study

17. Adenosine A

18. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology

19. Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex

20. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

21. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers

22. P.525 The relationship between synaptic density marker SV2A and glutamate: a multimodal positron emission tomography and magnetic resonance spectroscopy imaging study

23. O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS

24. Correction: Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans

25. Herbal Medicines in Neuropsychiatric Illness: The Case of L-Stepholidine

26. Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses

27. Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease

29. Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated With Antipsychotic Drugs—Linking Magnetic Resonance Imaging Findings to Cellular Pathology

31. Region-specific increases in the expression of translocator protein 18kDa (TSPO) after chronic exposure to haloperidol in naïve adult rats

32. Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107

33. Partial agonists in schizophrenia – why some work and others do not: insights from preclinical animal models

35. 40.3 MATERNAL IMMUNE ACTIVATION AND CHRONIC HALOPERIDOL INTERACT TO INCREASE MICROGLIAL ACTIVATION IN VIVO: DO ANTIPSYCHOTICS INFLAME THE BRAIN?

36. T193. CHRONIC HALOPERIDOL TREATMENT INDUCES SIGNIFICANT CHANGES IN MICROGLIA AND IN THE EXPRESSION OF THE 18 KDA TRANSLOCATOR PROTEIN TSPO IN NAIVE ADULT RAT BRAINS

37. Amisulpride the ‘atypical’ atypical antipsychotic — Comparison to haloperidol, risperidone and clozapine

38. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease

39. Evaluation of N-Desmethylclozapine as a Potential Antipsychotic—Preclinical Studies

40. The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat

41. Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration

42. Phosphodiesterase 10A PET radioligand development program:from pig to human

44. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations

45. Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment

47. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation

48. Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion

49. The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist

50. Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection

Catalog

Books, media, physical & digital resources